Pharma co Dr Reddy’s to reduce costs

HYDERABAD: Even as the threat of US tariffs on pharma imports looms large, Dr Reddy’s Laboratories is wielding the axe to cut flab and lower costs.

It is learnt that the company is laying off senior employees earning hefty packages across departments and also shutting down or rationalising headcount in certain businesses.

It is working on a target to cut workforce costs by 25% by laying off around 300-400 employees. It has asked many employees with annual pay packages of over Rs 1 crore to leave as part of the exercise. This is expected to lead to savings of up to Rs 1,300 crore, said a report.

Related Posts

DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

New Delhi — India’s top drug regulator has issued a nationwide alert over 90 fixed-dose combination (FDC) drugs being manufactured and sold without mandatory central approval, directing all state and…

India’s drug body flags 90 unapproved FDC medicines, states told to take action

The Central Drugs Standard Control Organisation (CDSCO), India’s top drug regulator, has identified at least 90 unapproved fixed-dose combination (FDC) medicines in circulation and asked states to move against those…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

India’s drug body flags 90 unapproved FDC medicines, states told to take action

India’s drug body flags 90 unapproved FDC medicines, states told to take action

India advancing as a global hub of affordable, quality healthcare solutions: Dr Jitendra Singh

India advancing as a global hub of affordable, quality healthcare solutions: Dr Jitendra Singh

Unapproved drops for dry eyes pose risks: Govt

Unapproved drops for dry eyes pose risks: Govt

Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward